Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TNDM | TANDEM DIABETES CARE INC | 2025-10-30 18:22:10 | 14.49 | -0.1 | -0.69 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNDM | 0001438133 | TANDEM DIABETES CARE INC | US8753722037 | 549300JEPFOD0K4D3I05 | 204327508 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 12400 HIGH BLUFF DRIVE | San Diego | CA | 92130 | UNITED STATES | US | 858-366-6900 | 12400 HIGH BLUFF DRIVE, San Diego, CA, 92130 | 12400 HIGH BLUFF DRIVE, San Diego, CA, 92130 | — | — | 2006 | John F. Sheridan | 1,500 | http://tandemdiabetes.com | 2,600,000,000 | 67,531,000 | 67,569,471 | Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy. | 2025-10-30 14:41:43 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,600,000,000 | 1,000,000,000 | 62.5 | 66,473,272 | 842,231 | 1.2833 |
| 2023 | 1,600,000,000 | -2,200,000,000 | -57.8947 | 65,631,041 | 1,102,982 | 1.7093 |
| 2022 | 3,800,000,000 | -1,600,000,000 | -29.6296 | 64,528,059 | 655,749 | 1.0267 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Elizabeth Gasser | Executive Vice President | 2024 | 450,203 | — | 1,307,627 | 239,863 | 7,778 | 2,005,471 |
| Jean-Claude Kyrillos | Chief Operating Officer, Executive Vice President | 2024 | 239,286 | — | 2,063,888 | 121,810 | 6,616 | 2,431,600 |
| John Sheridan | Chief Executive Officer, President | 2024 | 732,021 | — | 7,132,756 | 650,021 | 11,440 | 8,526,238 |
| Leigh Vosseller | Chief Financial Officer, Treasurer, Executive Vice President | 2024 | 450,203 | — | 1,783,115 | 239,863 | 6,900 | 2,480,081 |
| Susan Morrison | Chief Administrative Officer, Executive Vice President | 2024 | 450,203 | — | 1,307,627 | 239,863 | 7,778 | 2,005,471 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 2,650 |
| 2023 | 2,400 |
| 2022 | 2,600 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 940,203,000 | 747,718,000 | 801,217,000 |
| Cost Of Revenue | 450,629,000 | 380,028,000 | 388,231,000 |
| Gross Profit | 489,574,000 | 367,690,000 | 412,986,000 |
| Research And Development Expenses | 198,877,000 | 169,667,000 | 139,114,000 |
| General And Administrative Expenses | 389,824,000 | 352,503,000 | 335,681,000 |
| Operating Expenses | 588,701,000 | 600,920,000 | 505,834,000 |
| Operating Income | -99,127,000 | -233,230,000 | -92,848,000 |
| Net Income | -96,025,000 | -222,611,000 | -94,594,000 |
| Earnings Per Share Basic | -1.47 | -3.43 | -1.47 |
| Earnings Per Share Diluted | -1.47 | -3.43 | -1.47 |
| Weighted Average Shares Outstanding Basic | 65,451,000 | 64,969,000 | 64,146,000 |
| Weighted Average Shares Outstanding Diluted | 65,451,000 | 64,969,000 | 64,146,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 69,234,000 | 58,868,000 | 172,517,000 |
| Marketable Securities Current | 369,095,000 | 409,044,000 | 444,384,000 |
| Accounts Receivable | 114,585,000 | 105,555,000 | 114,717,000 |
| Inventories | 149,612,000 | 157,937,000 | 111,117,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 724,491,000 | 747,989,000 | 849,976,000 |
| Marketable Securities Non Current | 101,822,000 | 124,192,000 | 39,946,000 |
| Property Plant And Equipment | 78,150,000 | 76,542,000 | 68,552,000 |
| Other Assets Non Current | 5,166,000 | 40,336,000 | 23,631,000 |
| Total Assets Non Current | 243,167,000 | 204,669,000 | 202,809,000 |
| Total Assets | 967,658,000 | 952,658,000 | 1,052,785,000 |
| Accounts Payable | 44,730,000 | 49,586,000 | 55,730,000 |
| Deferred Revenue | 11,831,000 | 43,994,000 | 18,837,000 |
| Short Term Debt | 40,670,000 | — | — |
| Other Liabilities Current | 49,312,000 | 28,462,000 | 29,325,000 |
| Total Liabilities Current | 247,049,000 | 195,258,000 | 165,290,000 |
| Long Term Debt | 308,266,000 | 285,035,000 | 283,232,000 |
| Other Liabilities Non Current | 32,369,000 | 31,830,000 | 23,918,000 |
| Total Liabilities Non Current | 457,511,000 | 443,768,000 | 447,548,000 |
| Total Liabilities | 704,560,000 | 639,026,000 | 612,838,000 |
| Common Stock | 66,000 | 66,000 | 65,000 |
| Retained Earnings | -1,047,825,000 | -951,800,000 | -729,189,000 |
| Accumulated Other Comprehensive Income | -1,947,000 | 1,369,000 | -1,817,000 |
| Total Shareholders Equity | 263,098,000 | 313,632,000 | 439,947,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 14,700,000 | 13,800,000 | 12,300,000 |
| Share Based Compensation Expense | 101,383,000 | 88,076,000 | 84,918,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 20,795,000 | -4,277,000 | 7,830,000 |
| Change In Inventories | -5,810,000 | 46,053,000 | 42,452,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,392,000 | -4,864,000 | 24,493,000 |
| Change In Other Liabilities | 5,550,000 | 2,537,000 | -461,000 |
| Cash From Operating Activities | 24,225,000 | -31,810,000 | 50,464,000 |
| Purchases Of Marketable Securities | 264,311,000 | 510,859,000 | 467,652,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 19,231,000 | 26,804,000 | 34,097,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -23,482,000 | -85,740,000 | 33,168,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | -6,730,000 | 4,184,000 | 17,469,000 |
| Repurchase Of Common Stock | 30,000,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 183,000 | -71,000 | -675,000 |
| Cash From Financing Activities | 8,367,000 | 4,113,000 | 16,877,000 |
| Change In Cash | 10,366,000 | -113,649,000 | 101,336,000 |
| Cash At End Of Period | 69,234,000 | 58,868,000 | 172,517,000 |
| Income Taxes Paid | 3,098,000 | 1,923,000 | 411,000 |
| Interest Paid | 3,076,000 | 7,565,000 | 4,313,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.47 | -3.43 | -1.47 |
| Price To Earnings Ratio | -24.5034 | -8.6239 | -30.5782 |
| Earnings Growth Rate | -57.1429 | 133.3333 | -688 |
| Price Earnings To Growth Ratio | 0.4288 | -0.0647 | 0.0444 |
| Book Value Per Share | 4.0198 | 4.8274 | 6.8585 |
| Price To Book Ratio | 8.9607 | 6.1275 | 6.5539 |
| Ebitda | -70,812,000 | -197,006,000 | -75,675,000 |
| Enterprise Value | 2,637,247,020 | 2,147,950,020 | 2,994,077,700 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.3263 | 0.9088 | 0.6438 |
| Capital Expenditures | 16,308,000 | 21,790,000 | 30,466,000 |
| Free Cash Flow | 7,917,000 | -53,600,000 | 19,998,000 |
| Return On Equity | -0.365 | -0.7098 | -0.215 |
| One Year Beta | 1.5542 | 1.1117 | 1.5647 |
| Three Year Beta | 1.4817 | 1.3524 | 1.0725 |
| Five Year Beta | 1.1092 | 1.1349 | 1.1622 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | 2025-10-15 | 3,636 | A | 23,685 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | 2025-10-15 | 1,301 | D | 22,384 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | 2025-10-15 | 3,636 | D | 25,453 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER | 2025-09-15 | 7,415 | A | 36,214 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER | 2025-09-15 | 3,866 | D | 32,348 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2025-10-15 | NJ05 | Purchase | 2025-09-22 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2025-04-10 | NJ05 | Sale | 2025-03-19 | Joint | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-04-07 | CA31 | Purchase | 2025-03-04 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2024-09-11 | NJ05 | Purchase | 2024-08-05 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-08-13 | NY10 | Sale | 2023-07-12 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 2025-09-30 | 17,240,209 | 1,420,116 | 12.14 |
| Parkside Financial Bank & Trust | 2025-09-30 | 292 | 24 | 12.1667 |
| Covestor Ltd | 2025-09-30 | 8,000 | 696 | 11.4943 |
| Olympiad Research LP | 2025-09-30 | 201,803 | 16,623 | 12.14 |
| MIZUHO MARKETS AMERICAS LLC | 2025-09-30 | 1,424,775 | 117,362 | 12.14 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SHELTON FUNDS | 2025-08-31 | K Shares | SMLKX | 2,401 | 30,036.51 | 0.0581 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | SMCIX | 2,401 | 30,036.51 | 0.0581 |
| Global X Funds | 2025-08-31 | Global X HealthTech ETF | HEAL | 23,324 | 291,783.24 | 0.6527 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 721 | 9,019.71 | 0.0012 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 9,200 | 115,092 | 0.0095 |